11/5/2026

speaker
Conference Operator
Operator

Thank you for holding, ladies and gentlemen. The conference will begin momentarily. We thank you for your patience and ask that you please continue to hold. Ladies and gentlemen, please stand by. We are about to begin. Good day and welcome to the VeriCell Corporation third quarter 2026 earnings call. Today's conference is being recorded. If you would like to ask a question on today's call, please press star one on your telephone keypad. Now at this time, I would like to turn the conference over to Eric Burns, VeriCell VP of Finance and Investor Relations. Please go ahead, sir.

speaker
Eric Burns
VP of Finance and Investor Relations

Thank you, operator. and good morning everyone. Joining me on today's call are Verasol's President and Chief Executive Officer Nick Colangelo and our Chief Client Officer Joe Mara. Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to defer maturity and expectations are discussed more fully in the company's most recent filings with the SEC. The discussions today will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release, which is included as an exhibit to VeriCell's current report on Form 8-K, filed today with the SEC. A short presentation with highlights from today's call is also available in the investor relations section of our website. I will now turn the call over to Nick.

speaker
Nick Colangelo
President and Chief Executive Officer

Thank you, Eric, and good morning, everyone. The company had an outstanding third quarter, which was the strongest quarter of the year on a number of measures for the company, Macy, and our burn care business as we generated top-tier revenue growth across the portfolio, an inflection in profitability, and significant free cash flow. We delivered record third quarter total revenue of more than $85 million, which increased 26% over last year and significantly exceeded our guidance for the quarter. Based on our third quarter outperformance and the strong momentum that has continued into the fourth quarter, we're raising our full year total revenue guidance to $344 to $346 million, which represents 25% revenue growth for the year at the midpoint and an increase in revenue guidance of nearly $25 million since the start of the year. We also had another excellent quarter from a profitability perspective as net income nearly tripled, Adjusted EBITDA grew nearly 50% to more than $25 million and adjusted EBITDA margin increased to 30%, which was significantly higher than our guidance for the quarter. Based on this outperformance on profitability measures, we're also raising our adjusted EBITDA margin guidance for the year. Macy had another great quarter with record third quarter revenue of more than $67 million, which exceeded our guidance for the quarter and increased 21% versus the prior year, marking the sixth consecutive quarter with Macy revenue growth of 20% or more, which was notable given the significant acceleration in Macy implant and revenue growth in the third quarter of last year. Beyond Macy's strong revenue performance, we continue to see significant momentum in the underlying business fundamentals that support sustained Macy growth. We achieved record third quarter Macy biopsies, implants, and biopsy and implanting surgeons. Importantly, Macy's biopsy growth rate has increased each quarter this year, and we started the fourth quarter with the strongest biopsy month since launch in October. reflecting the strong demand that is translating into the robust implant procedure volume that supports our increased fourth quarter revenue guidance. With continued momentum across our key growth indicators and a strong start to the fourth quarter, we believe that Macy's is exceptionally well positioned to deliver a strong finish to the year and sustain its growth trajectory in 2027 and beyond. Macy's strong performance has been driven by the consistent high level of execution of our expanded Macy sales force, as well as the impact of the Macy-Arthur launch and our commercial excellence initiatives. The primary objective of our sales force expansion and commercial initiatives is to drive deeper penetration within Macy surgeon practices. And during the third quarter, we saw continued strength in biopsies per surgeon. a clear indicator that this initiative is beginning to unlock another key growth driver for Macy. In addition, the cohort of expansion territories has the highest biopsy growth rate for the first three quarters of the year, which we expect will lead to accelerating implant growth in our new territories in the fourth quarter and into 2027. Macy Arthro adoption also continues to gain momentum. We completed a record number of Macy-Arthro procedures in the third quarter, which represented the highest percentage of total Macy procedures in any quarter since launch. We also had a record high number of surgeons perform a Macy-Arthro procedure in the quarter, and more than 25% of Macy procedures to treat condyle defects under four square centimeters were administered via Macy-Arthro, another strong indicator of increasing adoption. While the patella defect segment continues to be our highest volume and growth segment, we've also seen higher growth and activity in other defect locations, which we believe is a result of the focus Macy-Arthro has created for these other defect segments. We expect that expanding Macy-Arthro adoption and utilization will be further supported by a growing body of positive clinical evidence. A recent publication evaluating patients treated arthroscopically outside the United States reported durable clinical outcomes and a higher rate of patient satisfaction at a mean follow-up of 13.6 years, reinforcing the potential long-term clinical benefits with the arthroscopic delivery of MACI. In addition, The first Macy-Arthro publication, which was published in August, highlighted several surgical and early patient outcome advantages of the Macy-Arthro procedure, including minimal surgical disruption to the joint, the ability to treat multiple cartilage defects in different compartments of the knee, a more desirable cosmetic appearance, and improved early postoperative recovery. These initial results suggest positive patient outcomes that could also lead to shorter overall rehab and recovery timelines for Macy-Arthro patients. Looking ahead, we expect our Macy Clinical Outcomes Registry to expand to even more sites in 2027, leading to additional data for future publications that can further enhance Macy's strong clinical profile. Surgeon engagement with Macy also continues to significantly expand as the number of peer-to-peer programs and training labs through the third quarter have more than tripled compared to last year. As we move into 2027, we expect an even greater impact from the expanded Macy sales force, Macy-Arthur adoption, and our commercial excellence initiatives, which together with continued overall trends towards restorative cartilage repair procedures positions Macy for sustained strong growth in 2027 and beyond. In terms of our longer-term Macy growth drivers, we continue to activate sites and enroll patients in the Macy ankle mascot study. As a reminder, a potential Macy ankle indication represents a substantial commercial opportunity for the company, with an estimated annual addressable market of nearly 20,000 patients, representing more than a $1 billion market opportunity. We also remain on track for the potential launch of Macy in the UK in the second half of 2027, which represents another meaningful market opportunity. Based on procedural data available from the UK National Health Service, we estimate an addressable market of approximately 15,000 patients annually, representing a potential market opportunity of several hundred million dollars. As we noted on our last call, we submitted a MESI marketing authorization application to the UK in the second quarter. The MHRA completed its inspection of our new manufacturing facility in the third quarter. And earlier this month, NICE accepted MESI for a single technology appraisal, which will establish reimbursement and pricing, as well as a specific MESI funding guidance for the NHS. In parallel, we've begun initial market development work to assess additional Macy OUS expansion opportunities in Canada and Europe. Finally, we're continuing to develop the next generation of Macy Arthro instruments as we remain focused on continuous innovation to further simplify and reduce surgical time for the Macy Arthro procedure and providing greater access for all areas of the knee, including for patella defects, which we expect will support sustained increases in surgeon engagement and Macy utilization. The company also delivered an exceptional quarter for the burn care business as we built on the momentum from the first half of the year and generated the highest quarterly revenue to date for both EpiCell and Nexabrid with record quarterly burn care revenue of $18 million, representing more than 50% growth versus both the prior year and the prior quarter. EpiCell's record quarterly revenue is driven by continued strength in biopsies and new biopsying centers as the burn care commercial team's cross-selling efforts continue to expand EpiCell adoption and utilization. Nexibrid's record quarterly commercial revenue was driven by the highest number of ordering burn centers and hospital orders in any quarter to date. Notably, we've added more new Nexabrid ordering centers through the third quarter of this year than during all of last year and have continued to expand the number of consistent users, an important driver of further uptake. To date, more than 80 centers have placed Nexabrid orders, with approximately 70 centers having placed repeat orders as we continue to focus on driving more centers to become consistent users. Building on the success with Macy, we've also recently implemented several commercial and operational excellence initiatives across BurnCare that we believe are beginning to have a meaningful impact on performance. For EpiCell, we began the year with a full commercial rebranding that refreshed the product's positioning around the critical importance of achieving wound closure, significantly increased our peer-to-peer activity, and sharpened our focus on supporting our surging customers with a multidisciplinary approach to drive the best clinical outcomes for patients. For Nexibrid, we've implemented similar account planning as well as stakeholder mapping initiatives that are leading to broader standardization of treatment algorithms across burn centers in more consistent adoption and utilization of Nexibrid. As we move into 2027, We believe that these commercial initiatives and our enhanced execution can drive continued strong results for the BurnCare franchise. Overall, we're on track to deliver a strong close to the year and another great year for the company. Our recent financial results and increased guidance demonstrate the company's unique combination of sustained high revenue growth, profitability, and cash generation. We believe that the durable growth of our portfolio positions the company to sustain strong revenue and profit growth in 2027 and the years ahead as we remain on track to achieve our midterm revenue and profitability targets. I'll now turn the call over to Joe to discuss our third quarter results and updated 2026 guidance in more detail.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API